Back to today’s briefing

Story perspectives

RSV Vaccine Cuts Hospitalizations by Nearly 10% in Seniors

9/3/2025

35 6

Summary

Story summary

The RSVpreF vaccine reduced all-cause cardiorespiratory hospitalizations by 9.9% in adults aged 60 and older.
The trial included 131,276 participants, indicating a need for further research on RSV immunization's cardioprotective effects.
Vaccination lowered RSV hospitalization risk by 58% over two seasons, with effectiveness decreasing over time, suggesting potential booster doses may be necessary.

1 of 1

Story summary

The RSVpreF vaccine reduced all-cause cardiorespiratory hospitalizations by 9.9% in adults aged 60 and older.
The trial included 131,276 participants, indicating a need for further research on RSV immunization's cardioprotective effects.
Vaccination lowered RSV hospitalization risk by 58% over two seasons, with effectiveness decreasing over time, suggesting potential booster doses may be necessary.